Prevalence of human respiratory syncytial virus circulating in Iran

详细信息    查看全文

• 作者：Vahid Salimi^a ; ^{vsalimi@sina.tums.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Masoumeh Tavakoli-Yaraki^b ; Jila Yavarian^a ; Louis Bont^c ; ^d ; Talat Mokhtari-Azad^a
• 关键词：RSV ; respiratory syncytial virus ; Flu ; influenza ; PIV ; parainfluenza ; AdV ; adenovirus ; hBoV ; human bocavirus ; hMPV ; human metapneumovirus
• 刊名：Journal of Infection and Public Health
• 出版年：2016
• 出版时间：March-April 2016
• 年：2016
• 卷：9
• 期：2
• 页码：125-135
• 全文大小：1360 K

文摘

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection during early childhood and is associated with a great burden on patients, parents, and society. While no treatment is yet available, results from recent phase 2 clinical trials of cell-entry inhibitors and RSV vaccines are promising. To prepare for introduction of these novel therapeutics, good understanding of its molecular epidemiology and continuous RSV surveillance data are necessary. This paper provides an overview of RSV prevalence and genotype distribution in Iran from 1996 to 2013. This meta-analysis includes 21 published studies. In total, 775 (18.7%) of 4140 respiratory specimens were positive for RSV infection. The male-female ratio of RSV-positive patients was 1.5:1. Significant peaks of RSV infection were detected during the cold season (November–March). RSV infection was mainly observed in patients <2 years of age. Phylogenetic studies showed that genotypes GA1, GA2, GA5, and BA co-circulated in Iran in 2007–2013. This review highlights the necessity of introducing standard molecular surveillance programs to inform the epidemiological, clinical, and pathological characteristics of various RSV genotypes. Improved understanding of the molecular epidemiology will be useful for development of novel RSV therapeutics.